medigraphic.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

2013, Número 6

<< Anterior Siguiente >>

Rev Invest Clin 2013; 65 (6)


La glicosilación de los anticuerpos y su efecto patogénico

Olivares N, Hernández-Pando R

Idioma: Español
Referencias bibliográficas: 42
Paginas: 515-523
Archivo PDF: 204.07 Kb.


RESUMEN

Las inmunoglobulinas de clase G (IgG) tienen unida covalentemente una cadena de azúcares en el fragmento cristalizable (Fc), estructura que está constituida por complejos glucosídicos bicatenarios con un alto grado de heterogeneidad que contribuyen en definir la afinidad de los Ac por sus receptores específicos, determinando en parte su actividad biológica. Recientemente se identificó un mecanismo antiinflamatorio mediado por las IgG con base en las diferentes alternativas de glicosilación del Fc y su interacción con el receptor de adhesión específico de células dendríticas (DC-SIGN). Este mecanismo ha tenido implicaciones clínicas y terapéuticas en los procesos autoinmunes. El objetivo de esta revisión es describir la estructura bioquímica de los azúcares asociados al Fc de la IgG, así como sus variantes en relación con las funciones específicas que éstas le confieren como factor patogénico en las enfermedades autoinmunes e infecciosas, particularmente en la tuberculosis donde también podría tener implicación terapéutica.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Jefferis R. Isotype and glycoform selection for antibody therapeutics. Arch Biochem Biophys 2012; 526(2): 159-66.

  2. Zauner G, Selman MH, Bondt A, Rombouts Y, Blank D, Deelder AM, Wuhrer M. Glycoproteomic analysis of antibodies. Mol Cell Proteomics 2013 [Epub ahead of print].

  3. Huhn C, Selman MH, Ruhaak LR, Deelder AM, Wuhrer M. IgG glycosylation analysis. Proteomics 2009; 9: 882-913.

  4. Stadlmann J, Pabst M, Altmann F. Analytical and Functional Aspects of Antibody Sialylation. J ClinImmunol 2010, 30 (Suppl. 1): S15-S19.

  5. Nimmerjahn F, Ravetch JV. Fc gamma receptors as regulators of immune responses. Nat Rev Immunol 2008; 8: 34-47.

  6. Murray RK. Glucoproteína En: Murray RK, Granner DK, Mayer PA, Rodwell VW (ed.) Harper’s Biochemistry. 10a ed. México, D.F.: El Manual Moderno; 2001.

  7. Anthony RM, Ravetch JV. A novel role for the IgG Fc glycan: the anti-inflammatory activity of sialylatedIgG Fcs. J Clin Immunol 2010; 30: S9-S14.

  8. Raju TS. Terminal sugars of Fc glycans influence antibody effector functions of IgGs. Curr Opin Immunol 2008; 20: 471-8.

  9. Jefferis R. Glycosylation of Antibody Therapeutics: Optimisation for Purpose. In: Faye L, Gomord V (ed.). Recombinant Proteins from Plants: Methods and Protocols Springer protocols, 2008.

  10. van der Poel CE, Spaapen RM, van de Winkel JG, Leusen JH. Functional characteristics of the high affinity IgG receptor, FcγRI. J Immunol 2011; 186(5): 2699-704.

  11. Abbas AK, Lichtman AH, Pillai S. Inmunología celular y molecular. 6a ed. Barcelona Elsevier; 2008.

  12. Jefferis R. Antibody therapeutics: isotype and glycoform selection. Expert Opin Biol Ther 2007; 7(9): 1401-13.

  13. Malhotra R, Wormald MR, Rudd PM, Fischer PB, Dwek RA, Sim RB. Glycosylation changes of IgG associated with rheumatoid arthritis can activate complement via the mannose-binding protein. Nat Med 1995; 1(3): 237-43.

  14. Hodoniczky J, Zheng YZ, James DC. Control of recombinant monoclonal antibody effector functions by Fc N-glycan remodeling in vitro. BiotechnolProg 2005; 21: 1644-52.

  15. Shields RL, Lai J, Keck R, Connell LY, Hong K, MengYG, Weikert SH, et al. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fc gamma RIII and antibody-dependent cellular toxicity. J Biol Chem 2002; 277: 26733-40.

  16. Scallon BJ, Tam SH, McCarthy SG, Cai AN, Raju TS. Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality. Mol Immunol 2007; 44(7): 1524-34.

  17. Zhou Q, Shankara S, Roy A, Qiu H, Estes S, McVie-Wylie A, Culm-Merdek K, et al. Development of a simple and rapid method for producing non-fucosylatedoligomannose containing antibodies with increased effector function. Biotechnol Bioeng 2008; 99: 652-65.

  18. Anthony RM, Kobayashi T, Wermeling F, Ravetch JV. Intravenous gammaglobulin suppresses inflammation through a novel T(H)2 pathway. Nature 2011; 475(7354): 110-3.

  19. Leader KA, Lastra GC, Kirwan JR, Elson CJ. Agalactosyl IgG in aggregates from the rheumatoid joint. Br J Rheumatol 1996; 35(4): 335-41.

  20. Ciriæ D, Milosevic-Jovcic N, Ilic V, Petrovic S. A longitudinal study of the relationship between galactosylation degree of IgG and rheumatoid factor titer and avidity during long-term immunization of rabbits with BSA. Autoimmunity 2005; 38(6): 409-16.

  21. Scherer HU, van der Woude D, Ioan-Facsinay A, el Bannoudi H, Trouw LA, Wang J, Häupl T, et al. Glycan profiling of anticitrullinated protein antibodies isolated from human serum and synovial fluid. Arthritis Rheum 2010; 62(6): 1620-9.

  22. Troelsen LN, Jacobsen S, Abrahams JL, Royle L, Rudd PM, Narvestad E, Heegaard NH, Garred P. IgG glycosylation changes and MBL2 polymorphisms: associations with markers of systemic inflammation and joint destruction in rheumatoid arthritis. J Rheumatol 2012; 39(3): 463-9.

  23. Tomana M, Schrohenloher RE, Koopman WJ, Alarcón GS, Paul WA. Abnormal glycosylation of serum IgG from patients with chronic inflammatory diseases. Arthritis Rheum 1988; 31(3): 333-8.

  24. Lood C, Allhorn M, Lood R, Gullstrand B, Olin AI, Rönnblom L, Truedsson L, et al. IgG glycan hydrolysis by endoglycosidase S diminishes the proinflammatory properties of immune complexes from patients with systemic lupus erythematosus: a possible new treatment? Arthritis Rheum 2012; 64(8): 2698-706.

  25. Wuhrer M, Porcelijn L, Kapur R, Koeleman CA, Deelder A, de Haas M, Vidarsson G. Regulated glycosylation patterns of IgG during alloimmune responses against human platelet antigens. J Proteome Res 2009; 8(2): 450-6.

  26. Misbah S, Kuijpers T, van der Heijden J, Grimbacher B, Guzman D, Orange J. Bringing immunoglobulin knowledge up to date: how should we treat today? Clin Exp Immunol 2011; 166(1): 16-25.

  27. Nimmerjahn F, Ravetch JV. Antibody-mediated modulation of immune responses. Immunol Rev 2010; 236: 265-75.

  28. Zhou T, Chen Y, Hao L, Zhang Y. DC-SIGN and immunoregulation. Cell Mol Immunol 2006; 3: 279-83.

  29. Albert H, Collin M, Dudziak D, Ravetch JV, Nimmerjahn F. In vivo enzymatic modulation of IgG glycosylation inhibits autoimmune disease in an IgG subclass-dependent manner. Proc- Natl Acad Sci USA 2008; 105: 15005-09.

  30. Anthony RM, Nimmerjahn F, Ashline DJ, Reinhold VN, Paulson JC, et al. Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science 2008; 320: 373-6.

  31. Guhr T, Bloem J, Derksen NI, Wuhrer M, Koenderman AH, Aalberse RC, Rispens T. Enrichment of sialylated IgG by lectin fractionation does not enhance the efficacy of immunoglobulin G in a murine model of immune thrombocytopenia. PLoS One 2011; 6(6): e21246.

  32. McCulloch J, Zhang YW, Dawson M, Harkiss GD, Peterhans E, Vogt HR, Lydyard PM, et al. Glycosylation of IgG during potentially arthritogenic lentiviral infections. Rheumatol Int 1995; 14: 243-8.

  33. Rademacher TW, Parekh RB, Dwek RA, Isenberg D, Rook G, Axford JS, Roitt I. The role of IgG glycoforms in the pathogenesis of rheumatoid arthritis. Springer Semin Immunopathol 1988; 10: 231-49.

  34. Glatman-Freedman A. The role of antibodies against tuberculosis. In: Mohd-Nor N, Acosta A, Sarmiento ME (eds.). The art and science of tuberculosis vaccine development. Selangor DurulEhsan, Malaysia. Oxford FajarSdn 2010; 81-107.

  35. Parekh R, Isenberg D, Rook G, Roitt I, Dwek R, Rademacher T. A Comparative Analysis of Disease-associated Changes in the Galactosylation of Serum IgG. Journal of Autoimmunity 1989; 2: 101-14.

  36. Olivares N, Puig A, Aguilar D, Moya A, Cádiz A, Otero O, et al. Prophylactic effect of administration of human gamma globulins in a mouse model of tuberculosis. Tuberculosis (Edinb) 2009; 89: 218-20.

  37. Roy E, Stavropoulos E, Brennan J, Coade S, Grigorieva E, Walker B, et al. Therapeutic efficacy of high-dose intravenous immunoglobulin in Mycobacterium tuberculosis infection in mice. Infect Immun 2005; 73: 6101-9.

  38. López Y, Yero D, Falero-Diaz G, Olivares N, Sarmiento ME, Sifontes S, et al. Induction of a protective response with an IgA monoclonal antibody against Mycobacterium tuberculosis 16 kDa protein in a model of progressive pulmonary infection. Int J Med Microbiol 2009; 6: 447-52.

  39. Arzuaga NO, Vila Granda A, JC Ramírez, San Miguel ME, Bourzac JF, Hernández YL, et al. The use of Streptomyces for immunization against mycobacterial infections. Hum Vaccin 2011; 7(9): 934-40.

  40. Acosta A, Norazmi MN, Sarmiento ME. Antibody mediated immunity-a missed opportunity in the fight against tuberculosis? Malays J Med Sci 2010; 17(2): 66-7.

  41. Olivares N, Marquina B, Mata D, Zatarain BL, Espitia C, Estrada GI, Parada C, et al. The protective effect in murine tuberculosis is dependent on IgG glycosilation. Pathog Dis 2013; 69(3): 176-83.

  42. Pradhan V, Patwardhan M, Athavale A, Taushid S, Ghosh K. Mycobacterium tuberculosis triggers autoimmunity? Indian J Tuberc 2012; 59(1): 49-5.




2020     |     www.medigraphic.com